Welcome to our dedicated page for NanoString Technologies news (Ticker: NSTG), a resource for investors and traders seeking the latest updates and insights on NanoString Technologies stock.
NanoString Technologies, Inc. (NASDAQ: NSTG) is a renowned provider of life science tools for translational research and molecular diagnostics. Established in 2008, NanoString's technology is pivotal in enabling a diverse array of basic research, translational medicine, and in vitro diagnostics applications. The company's flagship product, the nCounter® Analysis System, is celebrated for its ability to profile the expression of hundreds of genes, miRNAs, or copy number variations simultaneously with high sensitivity and precision. This system has been referenced in over 300 peer-reviewed publications, underscoring its widespread adoption and scientific credibility.
The nCounter® system's versatility extends to diagnostic use as the nCounter Dx Analysis System, further solidifying NanoString's footprint in the molecular diagnostics landscape. The technology stands out for its cost-effectiveness and efficiency, making it a valuable tool for applications such as biomarker discovery and validation, as well as other translational research endeavors.
Among recent developments, NanoString Technologies has been embroiled in significant litigation with 10x Genomics, Inc. Notably, the European Unified Patent Court (UPC) declined to issue a second preliminary injunction against NanoString, allowing the company to continue its operations in specific jurisdictions. However, injunctions from the Regional Court Munich I and the UPC still impose restrictions on the sale and service of NanoString's CosMx Spatial Molecular Imager (SMI) instruments and reagents for RNA detection in Europe.
The legal battles extend to the United States, where 10x Genomics has filed multiple suits against NanoString alleging patent infringement related to the GeoMx Digital Spatial Profiler and the CosMx SMI. Recently, a jury in the U.S. District Court for the District of Delaware awarded 10x Genomics over $31 million in damages, asserting that NanoString's GeoMx products willfully infringed on several patents.
Despite these legal challenges, NanoString continues to thrive as a leader in its field, providing essential tools that drive significant discoveries in oncology, immunology, neuroscience, and beyond. The company's commitment to advancing human health through molecular diagnostics and translational research tools remains unwavering.
NanoString Technologies (NASDAQ:NSTG) announced its upcoming presentation at the 41st Annual Cowen Healthcare Conference. CEO Brad Gray will present on March 3, 2021, at 12:20 PM ET. Interested parties can access the live webcast on the company’s website and will be available for replay one hour after the presentation, archived for 60 days. NanoString specializes in life science tools, including the nCounter Analysis System, which has been cited in over 4,000 peer-reviewed publications, and the GeoMx Digital Spatial Profiler for spatial profiling of RNA and proteins.
NanoString Technologies (NASDAQ:NSTG) announced the commercial launch of the Whole Transcriptome Atlas (WTA) for human and mouse tissue research, enhancing the GeoMx Digital Spatial Profiler (DSP) portfolio. The WTA provides a comprehensive view of all protein-coding genes and expands applications into neuroscience and developmental biology, complementing existing offerings in oncology and immunology. This launch signifies a key milestone for the company, with strong interest noted in its Technology Access Program. The WTA's capabilities will be showcased at the upcoming Spatial Genomics Summit on February 23.
NanoString Technologies, a leader in life science tools, will present at the 10th Annual SVB Leerink Global Healthcare Conference. CEO Brad Gray is set to speak on February 25th, 2021, at 10:00am ET. Interested listeners can access the live webcast and slides via the company's website, with a replay available one hour post-event for 60 days. The nCounter® Analysis System by NanoString is widely used in research, cited in over 4,000 publications, and supports biomarker discovery. For details, visit www.nanostring.com.
NanoString Technologies, Inc. (NASDAQ:NSTG) will disclose its fourth quarter and fiscal year 2020 results on March 1, 2021, after market close. A conference call hosted by company management will follow at 4:30 PM ET to discuss the results and provide a business update. Interested parties are encouraged to register in advance for the call. A replay will be accessible from March 1, 2021, at 7:30 PM ET until March 8, 2021. NanoString is recognized for its innovative life science tools, including the nCounter® Analysis System and GeoMx™ Digital Spatial Profiler.
NanoString Technologies (NASDAQ:NSTG) has announced a significant advancement in cancer research with the publication of a study in Nature Medicine utilizing its GeoMx® Digital Spatial Profiler (DSP) and Whole Transcriptome Atlas (WTA). Conducted by the Broad Institute, the study focuses on profiling sarcoma tissue and reveals novel insights into the immune response against synovial sarcoma. This peer-reviewed paper demonstrates GeoMx's capacity for high-plex spatial analysis, highlighting opportunities for future immunotherapy development.
NanoString Technologies, Inc. (NASDAQ:NSTG) reported strong preliminary financial results for Q4 and the fiscal year ending December 31, 2020, surpassing revenue expectations in all categories. The company generated $35.7 million in Q4 product and service revenue, driven by strong demand for its nCounter and GeoMx products. The total addressable market for spatial biology was updated to $12 billion, highlighting growth opportunities. Cash and short-term investments stood at approximately $440 million, indicating a solid financial position.
NanoString Technologies (NASDAQ:NSTG) has been recognized by Nature Methods as the Method of the Year for 2020 for its advancements in spatially-resolved transcriptomics. This recognition highlights the significance of spatial context in biological research, which has been enhanced by the introduction of the GeoMx® Digital Spatial Profiler (DSP). Launched in 2019, the GeoMx® DSP offers high-plex profiling capabilities, marking a major advancement in understanding cellular interactions. The company believes that innovations in spatial analysis will lead to significant advancements in functional genomics and precision medicine.
NanoString Technologies (NASDAQ:NSTG) announced its participation in the 39th Annual J.P. Morgan Virtual Healthcare Conference. CEO Brad Gray will present on January 13th, 2021, at 2:50 PM ET. The live webcast, including slides, will be accessible via the company’s investor website, with a replay available for 60 days post-event. NanoString is recognized for its nCounter® Analysis System, which has been cited in over 4,000 peer-reviewed publications, and its GeoMx® Digital Spatial Profiler, both pivotal in life sciences research.
NanoString Technologies (NASDAQ:NSTG) announced a peer-reviewed study published in Nature Communications that utilized its GeoMx® Digital Spatial Profiler (DSP) to analyze immune responses in SARS-CoV-2 infection. This study revealed crucial insights into the spatial heterogeneity of immune responses, highlighting the correlation between viral location and immune activity. The GeoMx DSP platform enabled high-plex spatial profiling of formalin-fixed samples, addressing challenges in COVID-19 research. The findings have potential implications for future therapeutic applications and clinical trials.
NanoString Technologies (NASDAQ:NSTG) has announced the development of a new spatial molecular imaging platform that allows for multiplexed analysis of RNA and protein expression at the single-cell level within tissue samples. This innovative solution leverages the company's advanced Hyb & Seq chemistry, capable of analyzing 1,000+ genes simultaneously. The platform aims to fill the gap for high-plex spatial analysis, enhancing research on cellular interactions in tumors and diseases. A full commercial launch is anticipated in the second half of 2022.
FAQ
What is the market cap of NanoString Technologies (NSTG)?
What is NanoString Technologies' primary business?
What is the nCounter® Analysis System?
What are some applications of NanoString's technology?
Has NanoString been involved in any legal issues recently?
What was the outcome of the recent lawsuit in the U.S. District Court for the District of Delaware?
What is the significance of the nCounter Dx Analysis System?
How many peer-reviewed publications have cited the nCounter® system?
What is the cost advantage of NanoString's technology?
What are the legal implications of the injunctions against NanoString in Europe?
How does NanoString contribute to advancements in human health?
